CA2216372C - Oral 2-methyl-thieno-benzodiazepine formulation - Google Patents
Oral 2-methyl-thieno-benzodiazepine formulation Download PDFInfo
- Publication number
- CA2216372C CA2216372C CA002216372A CA2216372A CA2216372C CA 2216372 C CA2216372 C CA 2216372C CA 002216372 A CA002216372 A CA 002216372A CA 2216372 A CA2216372 A CA 2216372A CA 2216372 C CA2216372 C CA 2216372C
- Authority
- CA
- Canada
- Prior art keywords
- formulation
- cellulose
- olanzapine
- hydroxypropyl
- methylcellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
The invention provides a pharmaceutically elegant solid oral formulation of olanzapine and a process for making such formulation. >
Description
'ORAL 2-METHYL-THIENO-B]3NZODIAZEPINE FORMULATION
This invention provides an improved pharmaceutically elegant tablet formulation of 2-methyl-4-(4-methyl-l-piperazinyl)-lOH-thieno[2,3-b][1,5] benzodiazepine, hereinafter referred to as olanzapine, and processes for the preparation thereof.
Olanzapine has shown great promise in the treatment of psychotic patients and in treating conditions selected from .10 psychosis, schizophrenia, schizophriform disorder, mild anx-iety and acute mania and is currently being evaluated for that purpose. Certain tablet formulations of olanzapine are known, as described in U.S. Patent No. 5,229,382. However, improved oral formulations were desired in light of the moisture sensitive, metastable nature of olanzapine, the tendency of olanzapine to undesirably discolor in the known tablet formulation, and due to the surprisingly potent nature of olanzapine.
,20 The presently claimed invention provides a pharmaceutically elegant solid oral formulation .comprising olanzapine intimately mixed with a bulking agent, binder, disintegrant.,' a dry binder to provide friability, and a lubricant.; wherein such solid oral formulation is coated with polymer selected from the group consisting of hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methylhydroxyethylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, polyvinyl pyrrolidone, dimethylaminoethyl methacrylatemethylacrylate acid ester copolymer, ethylacrylate-methylmethacrylate copolymer, methylcellulose, and ethylcellulose.
It is particularly preferred that the polymer coat .does not contain polyethylene glycol.
_ Further, the invention provides a method for preparing pharmaceutically elegant, stable solid oral olanzapine formulations having a polymer coat selected from -the.group consisting of hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methylhydroxyethylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, polyvinyl pyrrolidone, dimethylaminoethyl methacrylatemethylacrylate acid ester copolymer, ethylacrylate-methylmethacrylate copolymer, methylcellulose, and ethylcellulose_, comprised of using a high shear aqueous wet granulation with fluid bed drying process.
Olanzapine, a potent compound showing promising activity for use in treating psychotic patients, tends to be metastable, undergo pharmaceutically undesired discoloration, and demands care to assure homogeniety of_ the finished solid formulation.
Applicants have discovered that olanzapine undergoes undesirable discoloration when contacted with certain excipients including powder blends. Further, the discoloration is exacerbated by ambient air conditions,at elevated temperatures, and by moist environments.
Although the discoloration phenomenon does not produce an increase in the number of total related substances, the browning and mottling appearance is not generally considered pharmaceutically acceptable for commercial purposes. Further, the discoloration is particularly disturbing when a tablet formulation is administered to a psychotic patient, which patient may be especially troubled by the changing appearance of their medication.
Applicants have discovered that coating the solid oral formulation with a polymer selected from the group consisting of hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methylhydroxyethylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, polyvinyl pyrrolidone, dimethylaminoethyl methacrylatemethylacrylate acid ester copolymer, ethylacrylate-methylmethacrylate copolymer, methylcellulose, and ethylcellulose as a coating or subcoating provides a uniform, physical stability and effectively prevents the undesired discoloration phenomenon in the formulation. The formulation is most preferredly in a tablet form; however, granule formulation and the like are desired as well.
Most preferred polymer coats are hydroxypropyl methyl cellulose, hydroxypropylcellulose, methylcellulose, and ethylcellulose. An especially preferred polymer coat is hydroxypropyl methylcellulose.
It is especially preferred that the formulation contain the most stable anhydrous form of olanzapine, referred to herein as Form II; however, other forms of olanzapine are contemplated. Form II has a typical x-ray powder diffraction pattern as represented by the following interplanar spacings:
d (A) 10.2689 8.577 7.4721 7.125 .6.1459 6.071 5.4849 5.2181 5.1251 4.9874.
4.7665 4.7158 4.4787 4.3307 4:2294 4.141 3.9873 d 3.7206 3.5645 3.5366 3.3828 3.2516 3.134 3.0848 3.0638 3.0111 2.8739 2.8102 2.7217 2.6432 2.6007 A typical example of an x-ray diffraction pattern for Form II is as follows wherein d represents the interplanar spacing and i/I1 represents the typical relative intensities:
d (A) I/I1 10.2689 100.00 8.577 7.96 7.4721 1.41 7.125 6.50 6.1459 3.12 6.071 5.12 5.4849 0.52 5.2181 6.86 5.1251 2.47 4.9874 7.41 4.7665 4.03 4.7158 6.80 4.4787 14.72 4.3307 1.48 4.2294 23.19 4.141 11.28 3.9873 9.01 3.7206 14.04 3.5645 2.27 3.5366 4.85 3.3828 3.47 3.2516 1.25 3.134 0.81 .3.0848 0.45 3.0638 1.34 3.0111 3.51 2.8739 -0.79 2.8102 1.47 2.7217 0.20 2.6432 1.26 2.60-07 0.17 The x-ray diffraction patterns set out herein were obtained using a Siemens*D5000 x-ray powder diffractometer having a copper Ka radiation source of wavelength, X=1=541A.
The formulation of the invention preferredly contains substantially pure Form II as the active ingredient.
As used herein "substantially pure" refers to Form II associated with less than about 5% undesired.polymorphic form of olanzapine (herein referred to as "Undesired Forna"), preferably less than about 2% Undesired Form, and more preferably less than about 1% Undesired Form. Further,' "substantially pure" Form II will contain less than about 0.5% related substances, wherein "related substances". refers to undesired chemical impurities or residual solvent or water. In particular, "substantially pure" Form II
-preferably contain less than about 0.05% content of acetonitrile., more preferably,.less than about 0.005% content * Trade-mark of acetonitrile. Additionally, Form IT preferredly contain less than 0.5% of associated water.
As used herein, the term "mammal" shall refer to the Mammalia class of higher vertebrates. The term "mammal"
includes, but is not limited to, a human. The term "treating" as used herein includes prophylaxis of the named condition or amelioration or elimination of the condition once it has been established.
Form II is the most stable anhydrous form of olanzapine known and is therefore important for the commercial development of pharmaceutically elegant formulations. Olanzapine may form an undesired crystal form in the presence of certain solvents-and excipients, therefore, in making the compositions of the invention it is most desired to prepare the formulation using a method which does not require dissolution of the olanzapine substance. The desired Form II can be converted to less desirable polymorphic forms by contact with methylene chlori_de, for example. Additionally, for example, polyethylene glycol contact with the olanzapine substance produces undesired discoloration, particularly under moist conditi_ons.
Applicants believe that a dry blend direct compression process or dry granulated processes for preparing solid oral formulations create a greater chance that poor dose uniformity will occur. In-light of the.
potent nature of olanzapine, consistent dose uniformity is imperitive. In accordance with this invention, Applicants have discovered that a high shear aqueous wet granulation with fluid bed drying is the most effective method for preparing pharmaceutically elegant, stable, oral olanzapine formulations.
Uncoated tablets stored at ambient conditions (approximately 23 C and 40% relative humidity) in amber, high density polyethylene bottles do not show signs of discoloration after 24 months; however, if the bottle is opened such that the tablets are exposed to open air ambient conditions then discoloration occurs within 5 days.
A new solid oral formulation was prepared that used a hydroxypropropyl methylcellulose subcoating and a white color coating. The new formulation did not discolor after 90 days of open dish storage at 40 C,.60 C, 40 C/75 -%RH, ambient temperature with 75% RH, or at ambient temperature with 85% RH. The'hydroxypropyl methylcellulose coating which is free of polyethylene glycol is much preferred to ensure that discoloration does.not occur on the tablet surface. It provides an effective barrier between the white color coat which provides an acceptable medium for imprinting and color dressing of the product.
The hydroxypropylmethylcellulose coating provides sufficient barrier to prevent discoloration attributable to the polyethylene glycol in the white color coat.
Alternative white film coat formulas containing alternative plasticizers were evaluated; however, none were able to prevent discoloration in all test conditions after 90 days of storage. Therefore, the hydroxypropyl methylcellulose coat or subcoating is a surprising and important component of pharmaceutically elegant solid oral formulations of olanzapine.
A diluent or bulking agent-should be selected to provide an increase in tablet size. The artisan can utilize known methods to select a bulking agent which provides hardness, friability, and disintegration time that is satisfactory for pharmaceutical usage. The bulking agent should be selected to provide a tablet that has characterstics desired by the patient as-well as comply -with applicable regulatory guidelines.
One especially preferred diluent or bulking agent is lactose. A preferred amount appropriate for such formulations is from about 69.5 to about 87.5 $ w/w lactose.
'35 Various forms of lactose are appropriate for such formulations including anhydrous, hydrous, and spray dried forms. The most desired form of lactose can be selected based on desired dissolution, content uniformity;
hardness, friability, and disintegration time. -The skilled '8-artisan is aaware'of the regulatory requirements for hardness, friability, and disintegration time and can adjust the diluent or bulking agents using known techniques to achieve the desired physical characteristics.
The formulation should include a binder for use in the granulation step. The artisan can choose an appropriate binder based-on the acceptable viscosity, and desired hydration. iiydroxypropyl cellulose is especially preferred for use as a binder in the granulation step. A
preferred amount appropriate-for such formulation is from about 3.5 to about 4.5 t w/w hydroxypropyl cellulose. The hydroxypropyl cellulose may vary in particle size. Fa:ne grade hydroxypropyl cellulose is especially preferred for most claimed formulations.
The desired formulation includes a disintegrant for use in the granulation as well as in the running powders to facilitate the disintegration process. There are a variety of grades available, and the grade may be selected based on the acceptable batch variability. - A
particularly prefered disintegrant ir, crospovidone. A preferred amount appropriate for such formulation is from about 4 to about 6t w/w crospovidone. A fine grade of crospovidone provides particularly desirable consistency between batches.
The artisan may choose appropriate dxy binders using known methods. Such binders should be selected to - assure that satisfactory friability is attained. Most preferably, dry binder is microcrystalline cellulose;
however, other appropriate dry binders may be selected.
Such microdrystalline cellulose may be in a granular form. A
prefer.ro-d amount approp.riate for such forrmulati,on. is front.
about 9 to about 11 $ w/w microcrystalline cellulose.
The artisan can choose an appropriate lubricant to prevent sticking and picking of the tablets to the compression tooling. One preferred lubricant is magnesium stear- ate.. A preferred amount appropriate for such fotynu].ation is fromabout 0.25 to about 1t w/w magnesium sl:earate.
The artisan can readily choose other appropriate aqueous dispersion film coats (color mix) for application over the hydroxypropyl methylcellulose layer. Typically;
the color mixture is a dry blend of ingredients which ma~
te dispersed in water_'and used as an aqueous dispersion to t-ilm cOat solid formula.tions. thne example of a typical color mixture is comprised of hydr.o.-Cypropyl .. , ~
methylcellulose, polyethylene glycol, polysorbate 80, and titianium dioxide.
A variety of edible inks known to the artisan are appropriate for imprinting the finished formulation.
For example, one typical edible ink is comprised of shellac, ehtyl alcohol, isopropyl al.cohol, n-butyl alcohol, propylene glycol, ammonium hydroxide, and FD&C 8lue*
The solid formulation is most preferably subcoated with hydroxypropyl methylcellulose, coated with a color coat, and imprinted with an edible ink. The solid formulation may be polished using standard methods such as carnauba wax polishing, if desired.
Olanzapine is effective over a wide dosage range, the actual dose administered being dependent on the condition being treated. For example, in the treatment.of adult humans, dosages of from about 0.25 to 50 mg, preferably from 1 to 30 mg, and most preferably 1 to 20 mg per day may be used. A once a day dosage is normally sufficient, although divided doses may be administered.
For treatment of centra1 nervous system'disorders, a dose range,of from 1 to 30 mg, preferably 1 to 20 mg per day is suitable. Radiolabelled Form II 2-methyl-4-(4-methyl-i-piperazinyl)-10x-thieno-[2,3-b][1,5)-benzodiazepine, can be detected in the saliva and thus the compound can potentially be monitored in patients to assess compliance.
A preferred formulation of the invention is a solid oral formulation comprising from about 1 to about 20 mg olanzapine or from about 1 to 3% w/w as an active ingredient, wherein such solid oral formulation is coated with hydroxypropyl methylcellulose. Especially preferred is an oral formulation comprising from 1 to 20 mg of anhydrous Form.II
olanzapine as an effective amount of the active ingredient, as an effective amount'of the active ingredient, provided that such solid oral formulation is coated with hydroxypropyl methylcellulose. Especially preferred is a tablet solid oral formulation, wherein each tablet provides a dose of olanzapine that is 1, 2.5, 5, 7.5, 10, 15 or 20 mg.
Most preferably; the solid oral formulation is contained in packaging materials which protect the :Eormulation from moisture and. light. = For example, suitable * Trade-mark packaging materials include amber colored high density polyethylene bottles, amber colored glass bottles, and other containers made of a material which inhibits the passage of light. Most preferably, - the packaging will include a desiccant pack. The container may be sealed with an aluminum foil blister to provide the desired protection and maintain product stability.
-A study of the hydroxypropyl methylcellulose sub-coated tablets in an amber colored bottle having a desiccant pack stored at harsh, 40 C/75% RH conditions for six months showed pharmaceutically acceptable stability with a 0.4 t to about 1.2% increase in total related substances.
The materials for the present invention can be purchased or prepared by a variety of procedures well known to those of ordinary skill in the art. Olanzapine can be prepared as described by Chakrabarti in U.S. Patent No 5,229,382. It is most desirable to prepare a rapidly dissolving formulation comprising substantially pure crystalline Form II. Such substantially pure crystalline Form ii olanzapine may be prepared using the techniques described herein by the Preparation section herein infra.
Compound characterization methods include, for example, x-ray powder pattern analysis, thermogravimetric analysis (TGA), differential scanning calorimetery (DSC), titrametric analysis for water,-and Hl-NMR analysis for solvent content.
The formulations were studied to assure that the Form II polymorph was substantially pure using 13C Cross polarization / magic angle spinning (CP/MAS) NMR. Spectra were obtained using a Varian*Unity 400 MHz spectrometer operating at a carbon frequency of 100.577 MHz and equipped with a complete solids accessory and Varian 5 mm or 7 mm VT
CP/MAS probes. Measurement conditions were optimized for Olanzapine Form II and were as follows: 900 proton r.f.
pulse 4.5 ms, contact time 1.1 ms, pulse repetition time 5 s, MAS..frequency. T. 0. kHz, spectral width .50 kHz,. and acquisition * Trade-mark -~1-time 50 ms. Chemical shifts were referenced to the CH3 of hexamethylbenzene (d = 17.3 ppm) by sample replacement. It was determined that the substantially pure Form II polymorph is retained throughout the formulation process claimed herein. Therefore, the formulations of this invention provide substantially pure Form II olanzapine polymorph in a pharmaceutically elegant formulation without producing undesired polymorphic transformation.
The following examples are provided for purposes of illustration and are not to be construed as limiting the scope of the claimed invention.
Preflaratioa i Technical Grade olanzapine /N -NH2 N=HCt N
H~
'Intermediate 1 In a suitable three neck flask the following was added:
Dimethylsulfoxide (analytical): 6 volumes Intermediate 1 : 75 g N-Methylpiperazine (reagent) . 6 equivalents Intermediate 1 can be prepared using methods known to the skilled artisan. For example, the preparation of the Intermediate 1 is taught in U.S. Patent No. 5,229,382.
A sub-surface nitrogen sparge line was added to remove the ammonia formed during the reaction. The reaction was heated to 120 C and maintained at that temperature throughout the duration of the reaction. The reactions were followed by HPLC until <_ 5% of the intermediate 1 was left unreacted.
After the reaction was complete, the mixture was allowed to cool slowly to 20 C (about 2 hours). The reaction mixture was then transferred to an appropriate three neck round bottom flask and water bath. To this solution with agitation was added 10 volumes reagent grade methanol and the reaction was stirred at 20 C for 30 minutes. Three volumes of water was added slowly over about 30 minutes. The reaction slurry was cooled to zero to 5 C and stirred for 30 minutes. The product was filtered and the wet cake was washed with chilled methanol. The wet cake was dried in vacuo at 45 C overnight.
The product was identified as technical olanzapine.
Yield: 76.7%; Potency: 98.1%
Preparation 2 Form II
A 270 g sample of technical grade 2-methyl-4-(4-methyl-l-piperazinyl)-lOH-thieno[2,3-b][1,5]benzodiazepine was suspended in anhydrous ethyl acetate (2.7 L) . The mixture was heated to 76 C and maintained at 76 C for 30 minutes. The mixture was allowed to cool to 25 C. The resulting product was isolated using vacuum filtration. The product was identified as Form II using x-ray powder analysis.
Yield: 197 g.
The process described above for preparing Form II
provides a pharmaceutically elegant product having potency 97%, total related substances < 0.5% and an isolated yield of > 73%.
EXAMPLE I
A portion of the hydroxypropyl cellulose was dissolved in puri_fied water to form a solution for granulation. The remaining hydroxypropyl cellulose (total-of 4.0% w/w final tablet weight), which was an extra fine grade, was combined with the olanzapine (1.18% w/w), lactose (79.32%
w/w) and a portion of the crospovidone (5% w/w) in a high shear granulator. All ingredients were security sieved prior to addition and dry blended in the granulator. This mixture was then granulated with the hydroxypropyl cellulose solution in the high shear granulator. The granulation was wet sized using standard methods. The wet granulation was then dried in a fluidized bed dryer and sized. The material was then added to a tumble bin mixer.
The running powders consisting of microcrystalline cellulose (granular) (10% w/w), magnesium stearate (0.5% w/w), and the remainder of the crospovidone were added to the sized granulation. The mixture was blended and compressed with the appropriate tooling on tablet compression equipment.
Subcoating:
Hydroxypropyl methylcellulose (10% w/w) was mixed with purified water to form a solution. Core tablets were divided into approximately equal sections and spray coated with the hydroxypropyl methylcellulose solution . The operation was performed in a perforated coating pan.
Coatincr of Core Tablets:
Color Mixture White (hydroxypropyl methylcellulose, polyethylene glycol, polysorbate 80, and titanium dioxide) was mixed with purified water to form the coating suspension.
Subcoated tablets were divided into approximately equal sections and spray coated withthe coating suspension described above. The operation was performed in a perforated coating pan.
The coated tablets were lightly dusted with carnauba wax and impririted with appropriate identification.
The process substantially as described above in Example 1 was repeated using the following ingredients to provide pharmaceutically elegant tablet formulations containing 1, 2.5, 5, 7.5, and 10 mg olanzapine, respectively, per tablet:
1 mcr olanzapine per tablet: --Quantity Names of (mg/tab Ingredients let) Active Ingredient Olanzapine 1.0 Other Ingredients Lactose 67.43 Hydroxypropyl 3.40 Cellulose Crospovidone 4.25 Microcrystalline 8.50 Cellulose Magnesium Stearate 0.42 Subcoating Hydroxypropyl 1.70 Methylcellulose Coating Color Mixture White 3.47 Polishing Carnauba Wax trace Imprinting Edible Blue Ink trace olanzapine 2.5 mg Tablets Quantity Names of (mg/tab Ingredients let Active Ingredient Olanzapine 2.5 Other Ingredients Lactose 102.15 Hydroxypropyl 5.20 Cellulose Crospovidone 6.50 Microcrystalline 13.00 Cellulose Magnesium Stearate 0.65 Subcoating Hydroxypropyl 2.60 Methylcellulose Coating Color Mixture White 5.30 Polishing Carnauba Wax trace Imprinting Edible Blue Ink trace Olanzapine 5.0 ma Tablets Quantity Names of ( m g/ t a b Ingredients let) Active Ingredient Olanzapine 5.00 Other Ingredients Lactose 156.00 Hydroxypropyl 8.00 Cellulose Crospovidone 10.00 Microcrystalline 20.00 Cellulose Magnesium Stearate 1.00 Subcoating Hydroxypropyl 4.00 Methylcellulose = Coating Color Mixture White 8.16 Polishing Carnauba Wax trace Imprinting Edible Blue Ink trace Olanzapine 7.5 mcr Tablets Quantity Names of (mg/tab Ingredients let) Active Ingredient Olanzapine 7.50 Other Ingredients Lactose 234.00 Hydroxypropyl 12.00 Cellulose Crospovidone 15.00 Microcrystalline 30.00 Cellulose Magnesium Stearate 1.50 Subcoating Hydroxypropyl 6.00 Methylcellulose Coating Color Mixture White 12.24 Polishing Camauba Wax trace Imprinting Edible Blue Ink trace Olanzapine 10.0 mcr Tablets Quantity Names of (mg/tab Ingredients let) Active Ingredient Olanzapine 10.00 Other Ingredients Lactose 312.00 Hydroxypropyl 16.00 Cellulose Crospovidone 20.00 Microcrystalline 40.00 Cellulose Magnesium Stearate 2.00 Subcoating Hydroxypropyl 8.00 Methylcellulose Coating Color Mixture White 16.32 Polishing Carnauba Wax trace Imprinting Edible Blue Ink trace
This invention provides an improved pharmaceutically elegant tablet formulation of 2-methyl-4-(4-methyl-l-piperazinyl)-lOH-thieno[2,3-b][1,5] benzodiazepine, hereinafter referred to as olanzapine, and processes for the preparation thereof.
Olanzapine has shown great promise in the treatment of psychotic patients and in treating conditions selected from .10 psychosis, schizophrenia, schizophriform disorder, mild anx-iety and acute mania and is currently being evaluated for that purpose. Certain tablet formulations of olanzapine are known, as described in U.S. Patent No. 5,229,382. However, improved oral formulations were desired in light of the moisture sensitive, metastable nature of olanzapine, the tendency of olanzapine to undesirably discolor in the known tablet formulation, and due to the surprisingly potent nature of olanzapine.
,20 The presently claimed invention provides a pharmaceutically elegant solid oral formulation .comprising olanzapine intimately mixed with a bulking agent, binder, disintegrant.,' a dry binder to provide friability, and a lubricant.; wherein such solid oral formulation is coated with polymer selected from the group consisting of hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methylhydroxyethylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, polyvinyl pyrrolidone, dimethylaminoethyl methacrylatemethylacrylate acid ester copolymer, ethylacrylate-methylmethacrylate copolymer, methylcellulose, and ethylcellulose.
It is particularly preferred that the polymer coat .does not contain polyethylene glycol.
_ Further, the invention provides a method for preparing pharmaceutically elegant, stable solid oral olanzapine formulations having a polymer coat selected from -the.group consisting of hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methylhydroxyethylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, polyvinyl pyrrolidone, dimethylaminoethyl methacrylatemethylacrylate acid ester copolymer, ethylacrylate-methylmethacrylate copolymer, methylcellulose, and ethylcellulose_, comprised of using a high shear aqueous wet granulation with fluid bed drying process.
Olanzapine, a potent compound showing promising activity for use in treating psychotic patients, tends to be metastable, undergo pharmaceutically undesired discoloration, and demands care to assure homogeniety of_ the finished solid formulation.
Applicants have discovered that olanzapine undergoes undesirable discoloration when contacted with certain excipients including powder blends. Further, the discoloration is exacerbated by ambient air conditions,at elevated temperatures, and by moist environments.
Although the discoloration phenomenon does not produce an increase in the number of total related substances, the browning and mottling appearance is not generally considered pharmaceutically acceptable for commercial purposes. Further, the discoloration is particularly disturbing when a tablet formulation is administered to a psychotic patient, which patient may be especially troubled by the changing appearance of their medication.
Applicants have discovered that coating the solid oral formulation with a polymer selected from the group consisting of hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methylhydroxyethylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, polyvinyl pyrrolidone, dimethylaminoethyl methacrylatemethylacrylate acid ester copolymer, ethylacrylate-methylmethacrylate copolymer, methylcellulose, and ethylcellulose as a coating or subcoating provides a uniform, physical stability and effectively prevents the undesired discoloration phenomenon in the formulation. The formulation is most preferredly in a tablet form; however, granule formulation and the like are desired as well.
Most preferred polymer coats are hydroxypropyl methyl cellulose, hydroxypropylcellulose, methylcellulose, and ethylcellulose. An especially preferred polymer coat is hydroxypropyl methylcellulose.
It is especially preferred that the formulation contain the most stable anhydrous form of olanzapine, referred to herein as Form II; however, other forms of olanzapine are contemplated. Form II has a typical x-ray powder diffraction pattern as represented by the following interplanar spacings:
d (A) 10.2689 8.577 7.4721 7.125 .6.1459 6.071 5.4849 5.2181 5.1251 4.9874.
4.7665 4.7158 4.4787 4.3307 4:2294 4.141 3.9873 d 3.7206 3.5645 3.5366 3.3828 3.2516 3.134 3.0848 3.0638 3.0111 2.8739 2.8102 2.7217 2.6432 2.6007 A typical example of an x-ray diffraction pattern for Form II is as follows wherein d represents the interplanar spacing and i/I1 represents the typical relative intensities:
d (A) I/I1 10.2689 100.00 8.577 7.96 7.4721 1.41 7.125 6.50 6.1459 3.12 6.071 5.12 5.4849 0.52 5.2181 6.86 5.1251 2.47 4.9874 7.41 4.7665 4.03 4.7158 6.80 4.4787 14.72 4.3307 1.48 4.2294 23.19 4.141 11.28 3.9873 9.01 3.7206 14.04 3.5645 2.27 3.5366 4.85 3.3828 3.47 3.2516 1.25 3.134 0.81 .3.0848 0.45 3.0638 1.34 3.0111 3.51 2.8739 -0.79 2.8102 1.47 2.7217 0.20 2.6432 1.26 2.60-07 0.17 The x-ray diffraction patterns set out herein were obtained using a Siemens*D5000 x-ray powder diffractometer having a copper Ka radiation source of wavelength, X=1=541A.
The formulation of the invention preferredly contains substantially pure Form II as the active ingredient.
As used herein "substantially pure" refers to Form II associated with less than about 5% undesired.polymorphic form of olanzapine (herein referred to as "Undesired Forna"), preferably less than about 2% Undesired Form, and more preferably less than about 1% Undesired Form. Further,' "substantially pure" Form II will contain less than about 0.5% related substances, wherein "related substances". refers to undesired chemical impurities or residual solvent or water. In particular, "substantially pure" Form II
-preferably contain less than about 0.05% content of acetonitrile., more preferably,.less than about 0.005% content * Trade-mark of acetonitrile. Additionally, Form IT preferredly contain less than 0.5% of associated water.
As used herein, the term "mammal" shall refer to the Mammalia class of higher vertebrates. The term "mammal"
includes, but is not limited to, a human. The term "treating" as used herein includes prophylaxis of the named condition or amelioration or elimination of the condition once it has been established.
Form II is the most stable anhydrous form of olanzapine known and is therefore important for the commercial development of pharmaceutically elegant formulations. Olanzapine may form an undesired crystal form in the presence of certain solvents-and excipients, therefore, in making the compositions of the invention it is most desired to prepare the formulation using a method which does not require dissolution of the olanzapine substance. The desired Form II can be converted to less desirable polymorphic forms by contact with methylene chlori_de, for example. Additionally, for example, polyethylene glycol contact with the olanzapine substance produces undesired discoloration, particularly under moist conditi_ons.
Applicants believe that a dry blend direct compression process or dry granulated processes for preparing solid oral formulations create a greater chance that poor dose uniformity will occur. In-light of the.
potent nature of olanzapine, consistent dose uniformity is imperitive. In accordance with this invention, Applicants have discovered that a high shear aqueous wet granulation with fluid bed drying is the most effective method for preparing pharmaceutically elegant, stable, oral olanzapine formulations.
Uncoated tablets stored at ambient conditions (approximately 23 C and 40% relative humidity) in amber, high density polyethylene bottles do not show signs of discoloration after 24 months; however, if the bottle is opened such that the tablets are exposed to open air ambient conditions then discoloration occurs within 5 days.
A new solid oral formulation was prepared that used a hydroxypropropyl methylcellulose subcoating and a white color coating. The new formulation did not discolor after 90 days of open dish storage at 40 C,.60 C, 40 C/75 -%RH, ambient temperature with 75% RH, or at ambient temperature with 85% RH. The'hydroxypropyl methylcellulose coating which is free of polyethylene glycol is much preferred to ensure that discoloration does.not occur on the tablet surface. It provides an effective barrier between the white color coat which provides an acceptable medium for imprinting and color dressing of the product.
The hydroxypropylmethylcellulose coating provides sufficient barrier to prevent discoloration attributable to the polyethylene glycol in the white color coat.
Alternative white film coat formulas containing alternative plasticizers were evaluated; however, none were able to prevent discoloration in all test conditions after 90 days of storage. Therefore, the hydroxypropyl methylcellulose coat or subcoating is a surprising and important component of pharmaceutically elegant solid oral formulations of olanzapine.
A diluent or bulking agent-should be selected to provide an increase in tablet size. The artisan can utilize known methods to select a bulking agent which provides hardness, friability, and disintegration time that is satisfactory for pharmaceutical usage. The bulking agent should be selected to provide a tablet that has characterstics desired by the patient as-well as comply -with applicable regulatory guidelines.
One especially preferred diluent or bulking agent is lactose. A preferred amount appropriate for such formulations is from about 69.5 to about 87.5 $ w/w lactose.
'35 Various forms of lactose are appropriate for such formulations including anhydrous, hydrous, and spray dried forms. The most desired form of lactose can be selected based on desired dissolution, content uniformity;
hardness, friability, and disintegration time. -The skilled '8-artisan is aaware'of the regulatory requirements for hardness, friability, and disintegration time and can adjust the diluent or bulking agents using known techniques to achieve the desired physical characteristics.
The formulation should include a binder for use in the granulation step. The artisan can choose an appropriate binder based-on the acceptable viscosity, and desired hydration. iiydroxypropyl cellulose is especially preferred for use as a binder in the granulation step. A
preferred amount appropriate-for such formulation is from about 3.5 to about 4.5 t w/w hydroxypropyl cellulose. The hydroxypropyl cellulose may vary in particle size. Fa:ne grade hydroxypropyl cellulose is especially preferred for most claimed formulations.
The desired formulation includes a disintegrant for use in the granulation as well as in the running powders to facilitate the disintegration process. There are a variety of grades available, and the grade may be selected based on the acceptable batch variability. - A
particularly prefered disintegrant ir, crospovidone. A preferred amount appropriate for such formulation is from about 4 to about 6t w/w crospovidone. A fine grade of crospovidone provides particularly desirable consistency between batches.
The artisan may choose appropriate dxy binders using known methods. Such binders should be selected to - assure that satisfactory friability is attained. Most preferably, dry binder is microcrystalline cellulose;
however, other appropriate dry binders may be selected.
Such microdrystalline cellulose may be in a granular form. A
prefer.ro-d amount approp.riate for such forrmulati,on. is front.
about 9 to about 11 $ w/w microcrystalline cellulose.
The artisan can choose an appropriate lubricant to prevent sticking and picking of the tablets to the compression tooling. One preferred lubricant is magnesium stear- ate.. A preferred amount appropriate for such fotynu].ation is fromabout 0.25 to about 1t w/w magnesium sl:earate.
The artisan can readily choose other appropriate aqueous dispersion film coats (color mix) for application over the hydroxypropyl methylcellulose layer. Typically;
the color mixture is a dry blend of ingredients which ma~
te dispersed in water_'and used as an aqueous dispersion to t-ilm cOat solid formula.tions. thne example of a typical color mixture is comprised of hydr.o.-Cypropyl .. , ~
methylcellulose, polyethylene glycol, polysorbate 80, and titianium dioxide.
A variety of edible inks known to the artisan are appropriate for imprinting the finished formulation.
For example, one typical edible ink is comprised of shellac, ehtyl alcohol, isopropyl al.cohol, n-butyl alcohol, propylene glycol, ammonium hydroxide, and FD&C 8lue*
The solid formulation is most preferably subcoated with hydroxypropyl methylcellulose, coated with a color coat, and imprinted with an edible ink. The solid formulation may be polished using standard methods such as carnauba wax polishing, if desired.
Olanzapine is effective over a wide dosage range, the actual dose administered being dependent on the condition being treated. For example, in the treatment.of adult humans, dosages of from about 0.25 to 50 mg, preferably from 1 to 30 mg, and most preferably 1 to 20 mg per day may be used. A once a day dosage is normally sufficient, although divided doses may be administered.
For treatment of centra1 nervous system'disorders, a dose range,of from 1 to 30 mg, preferably 1 to 20 mg per day is suitable. Radiolabelled Form II 2-methyl-4-(4-methyl-i-piperazinyl)-10x-thieno-[2,3-b][1,5)-benzodiazepine, can be detected in the saliva and thus the compound can potentially be monitored in patients to assess compliance.
A preferred formulation of the invention is a solid oral formulation comprising from about 1 to about 20 mg olanzapine or from about 1 to 3% w/w as an active ingredient, wherein such solid oral formulation is coated with hydroxypropyl methylcellulose. Especially preferred is an oral formulation comprising from 1 to 20 mg of anhydrous Form.II
olanzapine as an effective amount of the active ingredient, as an effective amount'of the active ingredient, provided that such solid oral formulation is coated with hydroxypropyl methylcellulose. Especially preferred is a tablet solid oral formulation, wherein each tablet provides a dose of olanzapine that is 1, 2.5, 5, 7.5, 10, 15 or 20 mg.
Most preferably; the solid oral formulation is contained in packaging materials which protect the :Eormulation from moisture and. light. = For example, suitable * Trade-mark packaging materials include amber colored high density polyethylene bottles, amber colored glass bottles, and other containers made of a material which inhibits the passage of light. Most preferably, - the packaging will include a desiccant pack. The container may be sealed with an aluminum foil blister to provide the desired protection and maintain product stability.
-A study of the hydroxypropyl methylcellulose sub-coated tablets in an amber colored bottle having a desiccant pack stored at harsh, 40 C/75% RH conditions for six months showed pharmaceutically acceptable stability with a 0.4 t to about 1.2% increase in total related substances.
The materials for the present invention can be purchased or prepared by a variety of procedures well known to those of ordinary skill in the art. Olanzapine can be prepared as described by Chakrabarti in U.S. Patent No 5,229,382. It is most desirable to prepare a rapidly dissolving formulation comprising substantially pure crystalline Form II. Such substantially pure crystalline Form ii olanzapine may be prepared using the techniques described herein by the Preparation section herein infra.
Compound characterization methods include, for example, x-ray powder pattern analysis, thermogravimetric analysis (TGA), differential scanning calorimetery (DSC), titrametric analysis for water,-and Hl-NMR analysis for solvent content.
The formulations were studied to assure that the Form II polymorph was substantially pure using 13C Cross polarization / magic angle spinning (CP/MAS) NMR. Spectra were obtained using a Varian*Unity 400 MHz spectrometer operating at a carbon frequency of 100.577 MHz and equipped with a complete solids accessory and Varian 5 mm or 7 mm VT
CP/MAS probes. Measurement conditions were optimized for Olanzapine Form II and were as follows: 900 proton r.f.
pulse 4.5 ms, contact time 1.1 ms, pulse repetition time 5 s, MAS..frequency. T. 0. kHz, spectral width .50 kHz,. and acquisition * Trade-mark -~1-time 50 ms. Chemical shifts were referenced to the CH3 of hexamethylbenzene (d = 17.3 ppm) by sample replacement. It was determined that the substantially pure Form II polymorph is retained throughout the formulation process claimed herein. Therefore, the formulations of this invention provide substantially pure Form II olanzapine polymorph in a pharmaceutically elegant formulation without producing undesired polymorphic transformation.
The following examples are provided for purposes of illustration and are not to be construed as limiting the scope of the claimed invention.
Preflaratioa i Technical Grade olanzapine /N -NH2 N=HCt N
H~
'Intermediate 1 In a suitable three neck flask the following was added:
Dimethylsulfoxide (analytical): 6 volumes Intermediate 1 : 75 g N-Methylpiperazine (reagent) . 6 equivalents Intermediate 1 can be prepared using methods known to the skilled artisan. For example, the preparation of the Intermediate 1 is taught in U.S. Patent No. 5,229,382.
A sub-surface nitrogen sparge line was added to remove the ammonia formed during the reaction. The reaction was heated to 120 C and maintained at that temperature throughout the duration of the reaction. The reactions were followed by HPLC until <_ 5% of the intermediate 1 was left unreacted.
After the reaction was complete, the mixture was allowed to cool slowly to 20 C (about 2 hours). The reaction mixture was then transferred to an appropriate three neck round bottom flask and water bath. To this solution with agitation was added 10 volumes reagent grade methanol and the reaction was stirred at 20 C for 30 minutes. Three volumes of water was added slowly over about 30 minutes. The reaction slurry was cooled to zero to 5 C and stirred for 30 minutes. The product was filtered and the wet cake was washed with chilled methanol. The wet cake was dried in vacuo at 45 C overnight.
The product was identified as technical olanzapine.
Yield: 76.7%; Potency: 98.1%
Preparation 2 Form II
A 270 g sample of technical grade 2-methyl-4-(4-methyl-l-piperazinyl)-lOH-thieno[2,3-b][1,5]benzodiazepine was suspended in anhydrous ethyl acetate (2.7 L) . The mixture was heated to 76 C and maintained at 76 C for 30 minutes. The mixture was allowed to cool to 25 C. The resulting product was isolated using vacuum filtration. The product was identified as Form II using x-ray powder analysis.
Yield: 197 g.
The process described above for preparing Form II
provides a pharmaceutically elegant product having potency 97%, total related substances < 0.5% and an isolated yield of > 73%.
EXAMPLE I
A portion of the hydroxypropyl cellulose was dissolved in puri_fied water to form a solution for granulation. The remaining hydroxypropyl cellulose (total-of 4.0% w/w final tablet weight), which was an extra fine grade, was combined with the olanzapine (1.18% w/w), lactose (79.32%
w/w) and a portion of the crospovidone (5% w/w) in a high shear granulator. All ingredients were security sieved prior to addition and dry blended in the granulator. This mixture was then granulated with the hydroxypropyl cellulose solution in the high shear granulator. The granulation was wet sized using standard methods. The wet granulation was then dried in a fluidized bed dryer and sized. The material was then added to a tumble bin mixer.
The running powders consisting of microcrystalline cellulose (granular) (10% w/w), magnesium stearate (0.5% w/w), and the remainder of the crospovidone were added to the sized granulation. The mixture was blended and compressed with the appropriate tooling on tablet compression equipment.
Subcoating:
Hydroxypropyl methylcellulose (10% w/w) was mixed with purified water to form a solution. Core tablets were divided into approximately equal sections and spray coated with the hydroxypropyl methylcellulose solution . The operation was performed in a perforated coating pan.
Coatincr of Core Tablets:
Color Mixture White (hydroxypropyl methylcellulose, polyethylene glycol, polysorbate 80, and titanium dioxide) was mixed with purified water to form the coating suspension.
Subcoated tablets were divided into approximately equal sections and spray coated withthe coating suspension described above. The operation was performed in a perforated coating pan.
The coated tablets were lightly dusted with carnauba wax and impririted with appropriate identification.
The process substantially as described above in Example 1 was repeated using the following ingredients to provide pharmaceutically elegant tablet formulations containing 1, 2.5, 5, 7.5, and 10 mg olanzapine, respectively, per tablet:
1 mcr olanzapine per tablet: --Quantity Names of (mg/tab Ingredients let) Active Ingredient Olanzapine 1.0 Other Ingredients Lactose 67.43 Hydroxypropyl 3.40 Cellulose Crospovidone 4.25 Microcrystalline 8.50 Cellulose Magnesium Stearate 0.42 Subcoating Hydroxypropyl 1.70 Methylcellulose Coating Color Mixture White 3.47 Polishing Carnauba Wax trace Imprinting Edible Blue Ink trace olanzapine 2.5 mg Tablets Quantity Names of (mg/tab Ingredients let Active Ingredient Olanzapine 2.5 Other Ingredients Lactose 102.15 Hydroxypropyl 5.20 Cellulose Crospovidone 6.50 Microcrystalline 13.00 Cellulose Magnesium Stearate 0.65 Subcoating Hydroxypropyl 2.60 Methylcellulose Coating Color Mixture White 5.30 Polishing Carnauba Wax trace Imprinting Edible Blue Ink trace Olanzapine 5.0 ma Tablets Quantity Names of ( m g/ t a b Ingredients let) Active Ingredient Olanzapine 5.00 Other Ingredients Lactose 156.00 Hydroxypropyl 8.00 Cellulose Crospovidone 10.00 Microcrystalline 20.00 Cellulose Magnesium Stearate 1.00 Subcoating Hydroxypropyl 4.00 Methylcellulose = Coating Color Mixture White 8.16 Polishing Carnauba Wax trace Imprinting Edible Blue Ink trace Olanzapine 7.5 mcr Tablets Quantity Names of (mg/tab Ingredients let) Active Ingredient Olanzapine 7.50 Other Ingredients Lactose 234.00 Hydroxypropyl 12.00 Cellulose Crospovidone 15.00 Microcrystalline 30.00 Cellulose Magnesium Stearate 1.50 Subcoating Hydroxypropyl 6.00 Methylcellulose Coating Color Mixture White 12.24 Polishing Camauba Wax trace Imprinting Edible Blue Ink trace Olanzapine 10.0 mcr Tablets Quantity Names of (mg/tab Ingredients let) Active Ingredient Olanzapine 10.00 Other Ingredients Lactose 312.00 Hydroxypropyl 16.00 Cellulose Crospovidone 20.00 Microcrystalline 40.00 Cellulose Magnesium Stearate 2.00 Subcoating Hydroxypropyl 8.00 Methylcellulose Coating Color Mixture White 16.32 Polishing Carnauba Wax trace Imprinting Edible Blue Ink trace
Claims (17)
1. A solid oral formulation comprising olanzapine intimately mixed with a bulking agent, binder, disintegrant, a dry binder, and a lubricant; wherein said solid oral formulation is coated with a polymer selected from the group consisting of hydroxypropyl methylcellulose, hydroxyethyl cellulose, methylhydroxyethylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, polyvinyl pyrrolidone, dimethylaminoethyl methacrylatemethylacrylate acid ester copolymer, ethylacrylate-methylmethacrylate copolymer, methylcellulose, and ethylcellulose and wherein the polymer coating does not contain polyethylene glycol.
2. A formulation as claimed by Claim 1 wherein the polymer coat is selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropylcellulose, methylcellulose, and ethylcellulose.
3. A formulation as claimed by Claim 2 wherein the polymer coat is hydroxypropylmethyl cellulose.
4. A formulation as claimed by Claim 3 wherein the bulking agent is lactose.
5. A formulation as claimed by Claim 3 wherein the binder is hydroxypropyl cellulose and the disintegrant is crospovidone.
6. A formulation as claimed by any one of Claims 1 to 5 wherein the dry binder is microcrystalline cellulose.
7. A formulation as claimed by any one of Claims 1 to 6 wherein the lubricant is magnesium stearate.
8. A formulation as claimed by any one of Claims 1 to 7 wherein the hydroxypropyl methylcellulose coating is further, coated with a aqueous dispersion film coat.
9. A formulation as claimed by Claim 8 wherein the solid formulation is imprinted using an edible ink.
10. A formulation as claimed by Claim 8 wherein the formulation comprises from 1 to 3 % w/w olanzapine;
from 69.5 to 87.5 % w/w lactose; from 3.5 to 4.5 % w/w hydroxypropyl cellulose; from 4 to 6 % w/w crospovidone; from 9 to 11 % w/w microcrystalline cellulose; and from 0.25 to 1 %
magnesium stearate.
from 69.5 to 87.5 % w/w lactose; from 3.5 to 4.5 % w/w hydroxypropyl cellulose; from 4 to 6 % w/w crospovidone; from 9 to 11 % w/w microcrystalline cellulose; and from 0.25 to 1 %
magnesium stearate.
11. A formulation as claimed by any one of Claims 1 to wherein the solid formulation is a tablet.
12. A formulation as claimed by Claim 11 wherein each tablet provides a dose of olanzapine selected from the group consisting of 1, 2.5, 5, 7.5, 10, 15, and 20 mg.
13. A formulation as claimed by any one of Claims 1 to 12 wherein olanzapine is substantially pure Form II polymorph having an x-ray powder diffraction pattern as represented by the following interplanar spacings:
d ~(A) 10.2689 8.577 7.4721 7.125 6.1459 6.071 5.4849 5.2181 5.1251 4.9874 4.7665 4.7158 4.4787 4.3307 4.2294 4.141 3.9873 3.7206 3.5645 3.5366 3.3828 3.2516 3.134 3.0848 3.0638 3.0111 2.8739 ~
2.8102 2.7217 2.6432 2.6007
d ~(A) 10.2689 8.577 7.4721 7.125 6.1459 6.071 5.4849 5.2181 5.1251 4.9874 4.7665 4.7158 4.4787 4.3307 4.2294 4.141 3.9873 3.7206 3.5645 3.5366 3.3828 3.2516 3.134 3.0848 3.0638 3.0111 2.8739 ~
2.8102 2.7217 2.6432 2.6007
14. A process for preparing a stable solid oral formulation containing olanzapine comprising high shear aqueous wet granulation of olanzapine with one or more pharmaceutically acceptable excipient, fluid bed drying and coating with a polymer selected from the group consisting of hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methylhydroxyethylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, polyvinyl pyrrolidone, dimethylaminoethyl methacrylatemethylacrylate acid ester copolymer, ethylacrylate-methylmethacrylate copolymer, methylcellulose, and ethylcellulose, wherein the coating does not contain polyethylene glycol.
15. A process as claimed by Claim 14 wherein olanzapine is substantially pure Form II polymorph having an x-ray powder diffraction pattern as represented by the following interplanar spacings:
d (A) 10.2689 8.577 7.4721 7.125 6.1459 6.071 5.4849 5.2181 5.1251 4.9874 4.7665 4.7158 4.4787 4.3307 4.2294 4.141 3.9873 3.7206 3.5645 3.5366 3.3828 3.2516 3.134 3.0848 3.0638 3.0111 2.8739 2.8102 2.7217 2.6432 2.6007
d (A) 10.2689 8.577 7.4721 7.125 6.1459 6.071 5.4849 5.2181 5.1251 4.9874 4.7665 4.7158 4.4787 4.3307 4.2294 4.141 3.9873 3.7206 3.5645 3.5366 3.3828 3.2516 3.134 3.0848 3.0638 3.0111 2.8739 2.8102 2.7217 2.6432 2.6007
16. A solid formulation as claimed.by any one of Claims 1 to 13 for use in treating a condition selected from the group consisting of psychosis, schizophrenia, a schizophriform disorder, mild anxiety, and acute mania.
17. A solid oral formulation comprising olanzapine, wherein the formulation is coated with a polymer selected from hydroxypropyl methyl cellulose, hydroxethyl cellulose, methy hydroxethyl cellulose, sodium tcarboxymethyl cellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, dimethylaminoethyl methacrylate, methyl acrylate acid ester copolymer, ethyl acrylate-methyl methacrylate copolymer, methyl cellulose, and ethyl cellulose and wherein the polymer coating does not contain polyethylene glycol.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41046595A | 1995-03-24 | 1995-03-24 | |
| US08/410,465 | 1995-03-24 | ||
| PCT/US1996/003918 WO1996029995A1 (en) | 1995-03-24 | 1996-03-22 | Oral 2-methyl-thieno-benzodiazepine formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2216372A1 CA2216372A1 (en) | 1996-10-03 |
| CA2216372C true CA2216372C (en) | 2007-11-20 |
Family
ID=23624847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002216372A Expired - Lifetime CA2216372C (en) | 1995-03-24 | 1996-03-22 | Oral 2-methyl-thieno-benzodiazepine formulation |
Country Status (46)
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR5278A (en) * | 1995-03-24 | 1996-07-04 | Lilly Co Eli | ORAL FORMULATION OF 2-METHYL-THENO-BENZODIACEPINE |
| KR20000048540A (en) * | 1996-09-24 | 2000-07-25 | 피터 지. 스트링거 | Coated Particle Formulation |
| US20020035071A1 (en) * | 1997-07-08 | 2002-03-21 | Josef Pitha | Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites |
| US8563522B2 (en) * | 1997-07-08 | 2013-10-22 | The Iams Company | Method of maintaining and/or attenuating a decline in quality of life |
| US20060116330A1 (en) * | 1997-07-08 | 2006-06-01 | The Iams Company | Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose |
| US6617321B2 (en) | 1997-09-30 | 2003-09-09 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine formulation |
| US7022698B2 (en) | 1999-12-28 | 2006-04-04 | U & I Pharmaceuticals, Ltd. | Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof |
| US6348458B1 (en) | 1999-12-28 | 2002-02-19 | U & I Pharmaceuticals Ltd. | Polymorphic forms of olanzapine |
| EP1246827B1 (en) * | 1999-12-28 | 2005-04-13 | Cipla Limited | New polymorphic forms of olanzapine |
| US6740753B2 (en) | 2001-01-04 | 2004-05-25 | Geneva Pharmaceuticals, Inc. | Olanzapine crystal modification |
| US20030072731A1 (en) * | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing starch or dextrin |
| US20030072729A1 (en) * | 2001-05-15 | 2003-04-17 | Christopher Szymczak | Simethicone as weight gain enhancer |
| US20030070584A1 (en) | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
| US8309118B2 (en) | 2001-09-28 | 2012-11-13 | Mcneil-Ppc, Inc. | Film forming compositions containing sucralose |
| GB0203061D0 (en) * | 2002-02-08 | 2002-03-27 | Novartis Ag | Organic compounds |
| CA2477088A1 (en) | 2002-02-22 | 2003-10-02 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| WO2003086361A1 (en) * | 2002-04-18 | 2003-10-23 | Dr. Reddy's Laboratories Ltd. | Rapidly dispersing solid oral compositions |
| EP1513846B1 (en) | 2002-05-31 | 2011-03-02 | Sandoz Ag | Process of preparation of olanzapine form i |
| SI21270A (en) * | 2002-07-15 | 2004-02-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Crystal forms of olanzapine and procedures for their preparation |
| US7429619B2 (en) | 2002-08-02 | 2008-09-30 | Mcneil Consumer Healthcare | Polyacrylic film forming compositions |
| US7029112B2 (en) * | 2002-08-05 | 2006-04-18 | Mars, Incorporated | Ink-jet printing on surface modified edibles and products made |
| US8168170B2 (en) * | 2002-10-03 | 2012-05-01 | The Procter And Gamble Company | Compositions having an inner core and at least three surrounding layers |
| PL202856B1 (en) * | 2002-12-20 | 2009-07-31 | Adamed Spo & Lstrok Ka Z Ogran | Method of obtaining pharmaceutically pure polymorphic form of I olanzapine |
| WO2005009407A2 (en) * | 2003-07-29 | 2005-02-03 | Ranbaxy Laboratories Limited | Oral pharmaceutical formulations of olanzapine |
| CN1863517B (en) * | 2003-10-07 | 2011-08-03 | 安壮奇制药公司 | Rapidly disintegrating formulation |
| AU2004291043A1 (en) * | 2003-11-18 | 2005-06-02 | 3M Innovative Properties Company | Olanzapine containing transdermal drug delivery compositions |
| US8877178B2 (en) * | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
| US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
| US20050152884A1 (en) * | 2003-12-19 | 2005-07-14 | The Procter & Gamble Company | Canine probiotic Bifidobacteria globosum |
| US8894991B2 (en) * | 2003-12-19 | 2014-11-25 | The Iams Company | Canine probiotic Lactobacilli |
| US20050158294A1 (en) * | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
| ES2253091B1 (en) * | 2004-07-27 | 2007-02-01 | Inke, S.A. | MIXED SOLVATO OF OLANZAPINE, PROCEDURE FOR OBTAINING AND PROCEDURE OF OBTAINING THE FORM I OF OLANZAPINE FROM THE SAME. |
| EP1838716B1 (en) | 2005-01-05 | 2011-06-01 | Eli Lilly And Company | Olanzapine pamoate dihydrate |
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| PL385455A1 (en) * | 2005-04-22 | 2008-11-24 | Teva Pharmaceuticals Usa,Inc. | Oral disintegrating pharmaceutical tablet of olanzapine preparations |
| BRPI0611493B1 (en) * | 2005-05-31 | 2022-04-05 | Alimentary Health Ltd. | Feline probiotic lactobacilli |
| BRPI0611492B1 (en) * | 2005-05-31 | 2021-10-13 | Mars, Incorporated | BIFIDOBACTERIA PROBIOTICS FELINE |
| US20070014847A1 (en) * | 2005-07-05 | 2007-01-18 | Ahmed Salah U | Coated capsules and methods of making and using the same |
| BRPI0613611A2 (en) * | 2005-07-22 | 2011-01-18 | Myriad Genetics Inc | high concentration drug formulations and dosage forms |
| WO2007049304A2 (en) * | 2005-10-27 | 2007-05-03 | Jubilant Organosys Limited | Stable coated pharmaceutical formulation of olanzapine and process for preparing the same |
| GB0522474D0 (en) | 2005-11-03 | 2005-12-14 | Actavis Group | A pharmaceutical formulation |
| GB0522473D0 (en) * | 2005-11-03 | 2005-12-14 | Actavis Group | A pharmaceutical formulation |
| ES2279715B1 (en) * | 2005-12-26 | 2008-06-01 | Laboratorios Lesvi, S.L. | ORAL FORMULATION OF OLANZAPINE. |
| US7834176B2 (en) | 2006-01-26 | 2010-11-16 | Sandoz Ag | Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E |
| WO2007134845A2 (en) * | 2006-05-18 | 2007-11-29 | Synthon B.V. | Olanzapine pharmaceutical composition |
| CN101484141A (en) * | 2006-07-05 | 2009-07-15 | 比利姆制药工业和贸易公司 | A stable olanzapine formulation with antioxidants |
| AR063043A1 (en) * | 2006-09-29 | 2008-12-23 | Synthon Bv | PHARMACEUTICAL COMPOSITION OF OLANZAPINA |
| EP2124966B1 (en) | 2007-02-01 | 2015-09-09 | IAMS Europe B.V. | Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts |
| PT2246051E (en) * | 2008-01-31 | 2014-01-07 | Kyorin Seiyaku Kk | Method for production of orally rapidly disintegrating tablet comprising imidafenacin as active ingredient |
| US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
| US8505322B2 (en) * | 2009-03-25 | 2013-08-13 | Pax Scientific, Inc. | Battery cooling |
| US20110048048A1 (en) * | 2009-03-25 | 2011-03-03 | Thomas Gielda | Personal Cooling System |
| KR20120093060A (en) * | 2009-03-25 | 2012-08-22 | 카이틴, 아이엔씨. | Supersonic cooling system |
| US20110051549A1 (en) * | 2009-07-25 | 2011-03-03 | Kristian Debus | Nucleation Ring for a Central Insert |
| US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
| US8365540B2 (en) * | 2009-09-04 | 2013-02-05 | Pax Scientific, Inc. | System and method for heat transfer |
| WO2012153347A2 (en) | 2011-05-04 | 2012-11-15 | Zentiva K.S. | Oral pharmaceutical composition of olanzapine form 1 |
| HK1215170A1 (en) | 2012-11-14 | 2016-08-19 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| US9517212B1 (en) * | 2012-11-15 | 2016-12-13 | Chandra Zaveri | Medicated adhesive pad arrangement |
| CN103919782B (en) * | 2013-01-15 | 2016-12-28 | 天津药物研究院有限公司 | A kind of pharmaceutical composition containing olanzapine and preparation method thereof |
| EP3043778B1 (en) * | 2013-09-13 | 2017-09-06 | Bayer Pharma Aktiengesellschaft | Pharmaceutical compositions containing refametinib |
| CN107007559B (en) * | 2017-04-21 | 2020-05-15 | 浙江京新药业股份有限公司 | Stable oral pharmaceutical composition and preparation method thereof |
| AU2018275686B2 (en) * | 2017-06-02 | 2024-02-01 | Xeris Pharmaceuticals, Inc. | Precipitation resistant small molecule drug formulations |
| CN113143878A (en) * | 2021-03-19 | 2021-07-23 | 杭州新诺华医药有限公司 | Olanzapine composition and preparation method thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172831A (en) * | 1974-11-26 | 1979-10-30 | Lilly Industries Limited | Thieno-benzodiazepines |
| US4115568A (en) * | 1974-11-26 | 1978-09-19 | Lilly Industries Limited | Thieno[3,2-b]-[1,5]benzodiazepines |
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| US4820522A (en) * | 1987-07-27 | 1989-04-11 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| GB9009229D0 (en) * | 1990-04-25 | 1990-06-20 | Lilly Industries Ltd | Pharmaceutical compounds |
| ZA922777B (en) * | 1991-04-29 | 1993-10-15 | Lilly Co Eli | Pharmaceutical formulation containing dirithromycin |
| JPH05194225A (en) * | 1991-11-07 | 1993-08-03 | Yoshitomi Pharmaceut Ind Ltd | Stabilized anti-ulcer drug-containing preparation |
| NZ247703A (en) * | 1992-05-29 | 1995-07-26 | Lilly Industries Ltd | Thienobenzdiazepine derivatives and medicaments thereof |
| SE9302395D0 (en) * | 1993-07-09 | 1993-07-09 | Ab Astra | NEW PHARMACEUTICAL FORMULATION |
| US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
| CR5278A (en) * | 1995-03-24 | 1996-07-04 | Lilly Co Eli | ORAL FORMULATION OF 2-METHYL-THENO-BENZODIACEPINE |
| US5696115A (en) * | 1995-04-21 | 1997-12-09 | Eli Lilly And Company | Method for treating nicotine withdrawal |
-
1996
- 1996-03-12 CR CR5278A patent/CR5278A/en not_active Application Discontinuation
- 1996-03-21 EG EG25196A patent/EG24077A/en active
- 1996-03-22 BR BR9607791A patent/BR9607791A/en not_active IP Right Cessation
- 1996-03-22 DE DE69634053T patent/DE69634053T2/en not_active Expired - Lifetime
- 1996-03-22 DE DE69615887T patent/DE69615887T2/en not_active Expired - Lifetime
- 1996-03-22 HU HU9800410A patent/HU225269B1/en unknown
- 1996-03-22 AU AU54280/96A patent/AU696601B2/en not_active Ceased
- 1996-03-22 IL IL11761196A patent/IL117611A/en unknown
- 1996-03-22 GB GB9719817A patent/GB2313783B/en not_active Revoked
- 1996-03-22 EP EP96301997A patent/EP0733367B1/en not_active Expired - Lifetime
- 1996-03-22 KR KR1019970706592A patent/KR100408172B1/en not_active Expired - Fee Related
- 1996-03-22 PT PT00204708T patent/PT1093815E/en unknown
- 1996-03-22 PE PE1996000204A patent/PE44997A1/en not_active IP Right Cessation
- 1996-03-22 SI SI9630707T patent/SI1093815T1/en unknown
- 1996-03-22 TR TR97/01018T patent/TR199701018T1/en unknown
- 1996-03-22 DE DE19681287T patent/DE19681287T1/en not_active Ceased
- 1996-03-22 SK SK1282-97A patent/SK283745B6/en not_active IP Right Cessation
- 1996-03-22 JP JP8529533A patent/JPH11502848A/en active Pending
- 1996-03-22 SI SI9630404T patent/SI0733367T1/en unknown
- 1996-03-22 NZ NZ306111A patent/NZ306111A/en not_active IP Right Cessation
- 1996-03-22 AR ARP960101877A patent/AR002720A1/en not_active Application Discontinuation
- 1996-03-22 DK DK96301997T patent/DK0733367T3/en active
- 1996-03-22 EE EE9700328A patent/EE03551B1/en unknown
- 1996-03-22 MY MYPI96001086A patent/MY113440A/en unknown
- 1996-03-22 PT PT96301997T patent/PT733367E/en unknown
- 1996-03-22 ES ES00204708T patent/ES2232379T3/en not_active Expired - Lifetime
- 1996-03-22 EA EA199700260A patent/EA000938B1/en not_active IP Right Cessation
- 1996-03-22 ZA ZA9602338A patent/ZA962338B/en unknown
- 1996-03-22 AP APAP/P/1997/001064A patent/AP679A/en active
- 1996-03-22 TW TW085103453A patent/TW426526B/en not_active IP Right Cessation
- 1996-03-22 AT AT0902296A patent/AT405606B/en not_active IP Right Cessation
- 1996-03-22 RO RO97-01776A patent/RO118370B1/en unknown
- 1996-03-22 AT AT00204708T patent/ATE284695T1/en active
- 1996-03-22 CA CA002216372A patent/CA2216372C/en not_active Expired - Lifetime
- 1996-03-22 EP EP00204708A patent/EP1093815B1/en not_active Expired - Lifetime
- 1996-03-22 WO PCT/US1996/003918 patent/WO1996029995A1/en active IP Right Grant
- 1996-03-22 CO CO96014566A patent/CO4700474A1/en unknown
- 1996-03-22 AR AR33587496A patent/AR001405A1/en not_active Application Discontinuation
- 1996-03-22 ES ES96301997T patent/ES2164837T3/en not_active Expired - Lifetime
- 1996-03-22 AT AT96301997T patent/ATE206924T1/en active
- 1996-03-22 PL PL96322579A patent/PL188316B1/en unknown
- 1996-03-22 SI SI9620041A patent/SI9620041A/en unknown
- 1996-03-22 UA UA97094738A patent/UA44766C2/en unknown
- 1996-03-22 CH CH02246/97A patent/CH691217A5/en not_active IP Right Cessation
- 1996-03-22 FI FI973749A patent/FI973749A0/en unknown
- 1996-03-22 DK DK00204708T patent/DK1093815T3/en active
- 1996-03-22 CN CNB96192778XA patent/CN1178662C/en not_active Expired - Fee Related
- 1996-03-22 CZ CZ19973001A patent/CZ296007B6/en not_active IP Right Cessation
- 1996-09-20 US US08/716,922 patent/US5919485A/en not_active Expired - Lifetime
-
1997
- 1997-07-30 LU LU90115A patent/LU90115B1/en active
- 1997-09-05 SE SE9703206A patent/SE9703206D0/en not_active Application Discontinuation
- 1997-09-16 LT LT97-149A patent/LT4350B/en not_active IP Right Cessation
- 1997-09-22 BG BG101901A patent/BG62594B1/en unknown
- 1997-09-22 IS IS4565A patent/IS1903B/en unknown
- 1997-09-22 NO NO19974363A patent/NO320388B1/en not_active IP Right Cessation
- 1997-09-23 DK DK199701090A patent/DK173323B1/en not_active IP Right Cessation
- 1997-09-24 OA OA70083A patent/OA10511A/en unknown
- 1997-10-14 LV LVP-97-199A patent/LV11983B/en unknown
-
1998
- 1998-08-31 US US09/144,188 patent/US6190698B1/en not_active Expired - Lifetime
-
2001
- 2001-01-19 US US09/766,218 patent/US6780433B2/en not_active Expired - Fee Related
-
2004
- 2004-07-08 US US10/887,017 patent/US7229643B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2216372C (en) | Oral 2-methyl-thieno-benzodiazepine formulation | |
| AU719788B2 (en) | Coated particle formulation | |
| EP0900085B1 (en) | Treatment of excessive aggression with olanzapine | |
| HK1009754A (en) | Formulation comprising coated olanzapine particles | |
| MXPA97007186A (en) | Oral formulation of 2-methyl-tieno-benzodiazep |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20160322 |